Methods of potentiating HIV-1-specific CD8+ immune responses...

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S208100, C424S232100, C536S023720, C435S236000, C435S320100

Reexamination Certificate

active

07771729

ABSTRACT:
This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.

REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4837028 (1989-06-01), Allen
patent: 5019369 (1991-05-01), Presant et al.
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5174993 (1992-12-01), Paoletti
patent: 5187074 (1993-02-01), Treiber et al.
patent: 5192668 (1993-03-01), Treiber et al.
patent: 5204253 (1993-04-01), Sanford et al.
patent: 5279833 (1994-01-01), Rose
patent: 5308854 (1994-05-01), Hoffman, Jr. et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5476874 (1995-12-01), Hungate et al.
patent: 5502060 (1996-03-01), Thompson et al.
patent: 5578597 (1996-11-01), Spector et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5663169 (1997-09-01), Young et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5714374 (1998-02-01), Arnold et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 5846978 (1998-12-01), Coburn et al.
patent: 5863542 (1999-01-01), Paoletti et al.
patent: 5922687 (1999-07-01), Mann et al.
patent: 7094408 (2006-08-01), Franchini et al.
patent: 2004/0033237 (2004-02-01), Franchini et al.
patent: 2004/0191272 (2004-09-01), McMichael et al.
patent: WO-9804720 (1998-02-01), None
patent: WO-9856919 (1998-12-01), None
patent: WO-01-82964 (2001-11-01), None
Cox, W. I., et al., 1993, Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein, Virol. 195:845-850.
Evans, T. G., et al., 1999, A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers, J. Infect. Dis. 180:290-298.
PCT International Search Report in related application PCT/US 01/13968, (Oct. 6, 2001),6 Pages.
Illustrated Dictionary of Immunology, Definition of “vaccine”, Cruse, J.M., et al. (eds.), CRC Press, Inc., Boca Raton, FL,(1996),p. 309.
“Animal Models”,The NIAID Division of AIDS, Science, http://www.niaid.nih.gov/daids/vaccine/animals.htm, (Archived Jan. 23, 2000),2 Pages.
“Results from EV01 HIV Vaccine Trial, London and Lausanne, Jun. 7, 2004”, (EuroVac Press Release),(Jun. 2004),2 Pages.
Abaza, M.-S. I., et al., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin”,Journal of Protein Chemistry, 11, (1992),433-444.
Abimiku, A. G., et al., “Long-Term Survival of SIVmac251—Infected Macaques Previously Immunized with NYVAC-SIV Vaccines”,Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 15 (Supp 1), (1997),S78-S85.
ADIS International Ltd., “HIV gp120 vaccine—VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine—Genentech, HIV gp120 vaccine AIDSVAX—VaxGen, HIV vaccine AIDSVAX—VaxGen.”,Drugs R D., 4(4), (2003),249-53.
AIDS Vaccine Advocacy Coalition, “Support for the RV144 HIV vaccine trial”,Science, 305(5681), (Jul. 9, 2004),177-80.
Altman, J. D., et al., “Formation of Functional Peptide Complexes of Class II Major Histocompatibility Complex Proteins From Subunits Produced inEscherichia coli”, Pro. Natl. Acad. Sci. USA, 90, (1993),10330-10334.
Altman, J. D., et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes”,Science274, (1996),94-96.
Amara, Rama R., et al., “Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine”,Science, vol. 292, (Apr. 6, 2001),69-74.
Amara, R R., “Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques”,Virology, 334 (1), (Mar. 30, 2005),124-33.
Arp, J. , et al., “Human Immunodeficiency Virus Type 1 Envelope-Specific Cytotox T Lymphocytes Response Dynamics After Prime-Boost Vaccine Regimens With Human Immunodeficiency Virus Type 1 CanaryPox and Pseudovirions”,Viral Immunology, 12(4), (Abstract Only),(1999),1 Page.
Barnett, S. W., et al., “Prime-Boost Immunization Strategies against HIV”,AIDS Research and Human Retroviruses, 14, Supp. 3, (1998),S-299-S-309.
Bayes, M , “Gateways to clinical trials”,Methods Find Exp Clin Pharmacol., 26(4), (May 2004),295-318.
Benson, J. , et al., “Recombinant Vaccine-Induced Protection Against the Highly Pathogenic Simian Immunodeficiency Virus SIV mac251: Dependence on Route of Challenge Exposure”,Journal of Virology, 72(5), (1998),4170-4182.
Berzofsky, Jay A., et al., “Progress on new vaccine strategies against chronic viral infections”,The Journal of Clinical Investigation, vol. 114, No. 4, (Aug. 2004),450-462.
Bolesta, E , “Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens”,Virology, 332(2), (Feb. 20, 2005),467-79.
Boyer, Jean D., et al., “Vaccination of Seronegative Volunteers with a Human Immunodeficiency Virus Type 1 envlrev DNA Vaccine Induces Antigen-Specific Proliferation and Lymphocyte Production of â-Chemokines”,The Journal of Infectious Diseases, vol. 181, (2000),476-483.
Burton, D R., et al., “Public Health. A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials”,Science, 303(5656), (2004),316.
Carpenter, C. , et al., “Report of the NIH Panel to Define Principles of Therary of HIV Infection”,Morbidity and Mortality Weekly Report, 47 (RR-5), (Apr. 24, 1998),1-41.
Carroll, M. W., et al., “Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Progagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line”,Virology, 238(2), (1997),198-211.
Cohen, S. S., et al., “Pronounced Acute Immunosuppression in Vivo Mediated by HIV Tat Challenge”,Proceedings of the National Academy of Sciences of the U.S.A., 96, (Sep. 14, 1999),10842-10847.
Donnelly, J. J., et al., “DNA Vaccines”,Annu. Rev. Immunol., 15, (1997),617-648.
Dunbar, P. R., et al., “Direct Isolation, Phenotyping and Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes from Peripheral Blood”,Current Biology, 8, (1998),413-416.
Eloit, M. , et al., “Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine”,Journal of General Virology, 71(Pt. 10), (Oct. 1990),2425-2431.
Felgner, P. L., et al., “Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure”,Proc. Natl. Acad. Sci., USA, 84(21). (Nov. 1987),7413-7417.
Fuller, D. H., et al., “Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques”,Vaccine, 15(8), (1997),924-926.
Girard, M. , et al., “New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview”,C. R. Acad. Sci. Paris de la vie / Life Sci

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of potentiating HIV-1-specific CD8+ immune responses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of potentiating HIV-1-specific CD8+ immune responses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of potentiating HIV-1-specific CD8+ immune responses... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4150517

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.